
Bracco Receives Health Canada Approval for VUEWAY® injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging
MONTREAL, April 17, 2026 /PRNewswire/ — Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY® injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent (GBCA), for use in contrast-enhanced magnetic resonance imaging (CE-MRI).








